Compare LCTX & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | AMWL |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 111.4M |
| IPO Year | N/A | 2020 |
| Metric | LCTX | AMWL |
|---|---|---|
| Price | $1.71 | $4.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | $4.25 | ★ $7.58 |
| AVG Volume (30 Days) | ★ 1.4M | 141.4K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,816,000.00 | ★ $265,023,000.00 |
| Revenue This Year | $5.24 | N/A |
| Revenue Next Year | $126.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.05 | 4.33 |
| 52 Week Low | $0.37 | $3.71 |
| 52 Week High | $2.09 | $12.95 |
| Indicator | LCTX | AMWL |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 61.79 |
| Support Level | $1.65 | $3.92 |
| Resistance Level | $1.82 | $4.86 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 48.00 | 85.11 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.